Yuandong Biotech announced that in the first half of 2026, it achieved operating income of 659 million yuan, a year-on-year increase of 0.68%; net profit attributable to shareholders of listed companies was 130 million yuan, a year-on-year decrease of 4.99%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 93.6912 million yuan, a year-on-year decrease of 9.75%. R&D investment accounted for 24.10% of revenue, an increase of 3.85 percentage points over the previous year. Basic earnings per share were $0.74, down 3.90% year over year. There are no profit distribution plans for the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.